Wegovy Approved for Heart Disease Prevention
Med Page Today
MARCH 8, 2024
(MedPage Today) -- The FDA approved semaglutide (Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, the agency announced on Friday. A GLP-1 receptor.
Let's personalize your content